Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

Despite significant advances in disease modifying therapy in heart failure (HF), diuretics have remained the cornerstone of volume management in all HF phenotypes. Diuretics, alongside their definite acute haemodynamic and symptomatic benefits, also possess many possible deleterious side effects. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerr, Brian, Pharithi, Rebabonye B, Barrett, Matthew, Halley, Carmel, Gallagher, Joe, Ledwidge, Mark, McDonald, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Heart Failure 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536695/
https://www.ncbi.nlm.nih.gov/pubmed/36262879
http://dx.doi.org/10.36628/ijhf.2020.0043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536695/
https://www.ncbi.nlm.nih.gov/pubmed/36262879
http://dx.doi.org/10.36628/ijhf.2020.0043

Ejemplares similares